Literature DB >> 2824401

HSV-1 retinitis and delayed hypersensitivity in DBA/2 and C57BL/6 mice.

D Kielty1, S W Cousins, S S Atherton.   

Abstract

Following uniocular anterior chamber (a.c.) inoculation of HSV-1 into BALB/c mice, the architecture of the uninoculated eye is destroyed by a pan-retinal inflammatory process within 10 days. BALB/c inoculated with HSV-1 via the a.c. route also develop anterior chamber associated immune deviation (ACAID), one characteristic of which is impairment of virus-specific delayed hypersensitivity (DH) responsiveness. To determine whether other strains of mice develop ACAID and contralateral retinitis, DBA/2 and C57BL/6 mice were inoculated with HSV-1 (KOS strain) via the a.c. route. At intervals after inoculation, animals were examined clinically for evidence of retinitis in the uninoculated eye and were either (1) sacrificed for virus recovery studies or (2) ear-challenged for DH assays. Seven of 15 DBA/2 mice had clinical evidence of retinitis in the uninoculated eye by day 10 post-inoculation (p.i.). At this time, the average titer of virus in the uninoculated eyes was 3.37 log10 PFU/ml. Animals of this strain also had significantly impaired HSV-1 virus-specific DH responses consistent with ACAID. No (0/12) C57BL/6 developed contralateral retinitis; at day 10 p.i., the average virus titer in the uninoculated eyes of C57BL/6 mice was 1.10 log10 PFU/ml. Following a.c. inoculation of HSV-1, C57BL/6 mice developed vigorous DH responses comparable to those of subcutaneously immunized, DH-positive animals. The results of these experiments suggest that different strains of mice vary in their susceptibility to HSV-1 retinitis and that the development of retinitis is linked to the amount of virus in the uninoculated eye.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 2824401

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  Protection of mice from herpes simplex virus-induced retinitis by in vitro-activated immune cells.

Authors:  J U Igietseme; P J Calzada; A R Gonzalez; J W Streilein; S S Atherton
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  Oligoadenylate synthetase/protein kinase R pathways and alphabeta TCR+ T cells are required for adenovirus vector: IFN-gamma inhibition of herpes simplex virus-1 in cornea.

Authors:  Bobbie Ann Austin; William P Halford; Bryan R G Williams; Daniel J J Carr
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

3.  Role of Th1 and Th2 cells in anterior chamber-associated immune deviation.

Authors:  X Y Li; L T D'Orazio; J Y Niederkorn
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

4.  Mechanisms of protection against herpes simplex virus type 1-induced retinal necrosis by in vitro-activated T lymphocytes.

Authors:  J U Igietseme; J W Streilein; F Miranda; S J Feinerman; S S Atherton
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

5.  Kinetics of serum, tear, and corneal antibody responses in resistant and susceptible mice intracorneally infected with Pseudomonas aeruginosa.

Authors:  M J Preston; K A Kernacki; J M Berk; L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

6.  Necrotizing chorioretinitis in mice inoculated with herpes simplex virus type 1 with or without glycoprotein C: anterior chamber-associated immune deviation does not persist.

Authors:  Y Liu; H Minagawa; Y Toh; Y Sakai; T Ishibashi; H Inomata; R Mori
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

7.  Induction of bilateral retinal necrosis in mice by unilateral intracameral inoculation of a glycoprotein-C deficient clinical isolate of herpes simplex virus type 1.

Authors:  Y Liu; Y Sakai; H Minagawa; Y Toh; T Ishibashi; H Inomata; R Mori
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

8.  Role of NKT cells in anterior chamber-associated immune deviation.

Authors:  Jerry Y Niederkorn
Journal:  Expert Rev Clin Immunol       Date:  2009-03       Impact factor: 4.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.